BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38022678)

  • 21. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
    Duraiswamy J; Turrini R; Minasyan A; Barras D; Crespo I; Grimm AJ; Casado J; Genolet R; Benedetti F; Wicky A; Ioannidou K; Castro W; Neal C; Moriot A; Renaud-Tissot S; Anstett V; Fahr N; Tanyi JL; Eiva MA; Jacobson CA; Montone KT; Westergaard MCW; Svane IM; Kandalaft LE; Delorenzi M; Sorger PK; Färkkilä A; Michielin O; Zoete V; Carmona SJ; Foukas PG; Powell DJ; Rusakiewicz S; Doucey MA; Dangaj Laniti D; Coukos G
    Cancer Cell; 2021 Dec; 39(12):1623-1642.e20. PubMed ID: 34739845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.
    Beckermann KE; Hongo R; Ye X; Young K; Carbonell K; Healey DCC; Siska PJ; Barone S; Roe CE; Smith CC; Vincent BG; Mason FM; Irish JM; Rathmell WK; Rathmell JC
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Modification of Tumor-Infiltrating Lymphocytes
    Weinstein-Marom H; Gross G; Levi M; Brayer H; Schachter J; Itzhaki O; Besser MJ
    Front Immunol; 2020; 11():584148. PubMed ID: 33488585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
    Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
    J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
    Sun S; Huang C; Lu M; Xu H; Yuan Y; Zhao W; Hu X; Wang B; Zhang W; Gao X; Zheng J; Su L; Zhang Q
    Cancer Immunol Res; 2023 Apr; 11(4):515-529. PubMed ID: 36689620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
    Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
    Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
    Janardhan SV; Praveen K; Marks R; Gajewski TF
    PLoS One; 2011; 6(9):e24931. PubMed ID: 21949793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human autologous tumor-specific T cells in malignant melanoma.
    Platsoucas CD
    Cancer Metastasis Rev; 1991 Jun; 10(2):151-76. PubMed ID: 1873855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
    Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
    Liu H; Qiu F; Wang Y; Zeng Q; Liu C; Chen Y; Liang CL; Zhang Q; Han L; Dai Z
    Front Immunol; 2019; 10():306. PubMed ID: 30863408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
    Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
    Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.